Assignee
BIONTECH CELL & GENE THERAPIES GMBH
DE·9 granted patents·14 pending applications·8 citations·filing 2015–2024
Top patents by PatentIndex Score
23 records- 0179US11713346B2Claudin-18.2-specific immunoreceptors and T cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2016·Granted Aug 1, 2023·2 cites·28 claims
- 0279US10370423B2Claudin-6-specific immunoreceptors and T cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2015·Granted Aug 6, 2019·4 cites·8 claims
- 0378US2026091060A1Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2024·Application pending·0 cites
- 0474US11702631B2Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2018·Granted Jul 18, 2023·2 cites·15 claims
- 0574US2022288180A1Antigen-specific t cell receptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Application pending·0 cites
- 0673US12559531B2Claudin-6-specific immunoreceptors and T cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Granted Feb 24, 2026·0 cites·7 claims
- 0770US2024287155A1Rna replicon for expressing at cell receptor or an artificial t cell receptorBIONTECH CELL & GENE THERAPIES GMBH·Filed 2023·Application pending·0 cites
- 0870US2023119334A1Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Application pending·0 cites
- 0969US11311611B2Antigen-specific T cell receptors and T cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2018·Granted Apr 26, 2022·0 cites·16 claims
- 1067US11345731B2Claudin-6-specific immunoreceptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2019·Granted May 31, 2022·0 cites·12 claims
- 1167US2023303656A1Claudin-18.2-specific immunoreceptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2023·Application pending·0 cites
- 1266US2022033461A1Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2021·Application pending·0 cites
- 1360US12186275B2Enhancing the effect of CAR-engineered T cells by means of nucleic acid vaccinationBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Granted Jan 7, 2025·0 cites·29 claims
- 1455US2020283497A1Rna replicon for expressing at cell receptor or an artificial t cell receptorBIONTECH CELL & GENE THERAPIES GMBH·Filed 2018·Application pending·0 cites
- 1554US10799534B2Enhancing the effect of car-engineered T cells by means of nucleic acid vaccinationBIONTECH CELL & GENE THERAPIES GMBH·Filed 2016·Granted Oct 13, 2020·0 cites·18 claims
- 1651US2025339533A1Agents and methods for activation and targeting of immune effector cellsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2022·Application pending·0 cites
- 1748US2023000962A1Treatment involving immune effector cells genetically modified to express antigen receptorsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 1848US2018282390A1Antigen receptors and uses thereofBIONTECH CELL & GENE THERAPIES GMBH·Filed 2016·Application pending·0 cites
- 1946US2023405046A1Antigen-specific t cell receptors and t cell epitopesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2021·Application pending·0 cites
- 2045US2022125836A1Treatment involving car-engineered t cells and cytokinesBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 2144US2023049655A1In vitro and in vivo gene delivery to immune effector cells using nanoparticles functionalized with designed ankyrin repeat proteins (darpins)BIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
- 2243US12595292B2Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cellsBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Granted Apr 7, 2026·0 cites·16 claims
- 2341US2022184119A1Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancersBIONTECH CELL & GENE THERAPIES GMBH·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when BIONTECH CELL & GENE THERAPIES GMBH files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →